Grundlagen und Besonderheiten der Transfusionstherapie bei
                    Hämoglobinopathien

H. Cario; C. Weinstock; B. Mayer; S. Lobitz

doi:10.1055/s-0032-1324992

Transfusionsmedizin, Inhaltsverzeichnis

Transfusionsmedizin 2013; 3(2): 92-110
DOI: 10.1055/s-0032-1324992

CME-Fortbildung

Georg Thieme Verlag KG Stuttgart · New York

Grundlagen und Besonderheiten der Transfusionstherapie bei Hämoglobinopathien

H. Cario

¹Kinder-Hämatologie und ‑Onkologie, Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Ulm

,

C. Weinstock

²Institut für Klinische Transfusionsmedizin und Immungenetik Ulm, DRK-Blutspendedienst Baden-Württemberg – Hessen und Institut für Transfusionsmedizin, Universität Ulm

,

B. Mayer

³Institut für Transfusionsmedizin, Charité-Universitätsmedizin Berlin

,

S. Lobitz

⁴Klinik für Pädiatrie mit Schwerpunkt Onkologie/Hämatologie/KMT, Charité-Universitätsmedizin Berlin

› Institutsangaben

Abstract

Zusammenfassung

Die Thalassämien und die Sichelzellkrankheit gehören zu den häufigsten monogen vererbten Erkrankungen weltweit. In Deutschland und Mitteleuropa sind sie hingegen selten; es sind nahezu ausschließlich Menschen mit Migrationshintergrund davon betroffen. Die Transfusion von Erythrozytenkonzentraten ist zentraler Bestandteil der Therapie beider Krankheitsgruppen. Dabei bestehen grundlegende Unterschiede hinsichtlich Ziel, Indikation und Durchführung der transfusionsmedizinischen Behandlung. Während bei der Thalassaemia major die regelmäßige Transfusionstherapie mit dem Ziel der weitestgehenden Unterdrückung der Eigenerythropoese essenziell ist, bestehen bei der Sichelzellkrankheit nur wenige, ausgewählte Indikationen für eine regelmäßige Transfusions- bzw. Austauschtransfusionstherapie, die dort vor allem das Ziel hat, den HbS-Anteil (HbS: Sichelzellenhämoglobin) niedrig zu halten, um Komplikationen, insbesondere ZNS-Infarkte (ZNS: Zentralnervensystem), zu vermeiden. Im Gegensatz zur Thalassämie gibt es bei der Sichelzellkrankheit Indikationen für ereignisbezogene Einzel- oder Austauschtransfusionen, z. B. bei Milzsequestrationskrise und bei akutem Thoraxsyndrom. Sowohl bei den Thalassämien als auch bei der Sichelzellkrankheit spielen Allo- und Autoimmunisierung gegen erythrozytäre Antigene eine wichtige Rolle, sodass die erweiterte Untersuchung von Blutgruppenantigenen und die Auswahl entsprechend kompatibler Erythrozytenkonzentrate von Beginn der Transfusionstherapie an von großer Bedeutung sind.

Key words

Thalassämie - Sichelzellkrankheit - Hämoglobinopathie - Transfusion - Austauschtransfusion - Erythrozytapherese - Eisenüberladung - Hämochromatose

Volltext

Referenzen

Literatur
1 Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005; 353 (11) 1135-1146
2 Kohne E, Kleihauer E. Hämoglobinopathien – eine Langzeitstudie über vier Jahrzehnte. Dtsch Arztebl Int 2010; 107 (5) 65-71
3 Weatherall DJ, Clegg JB. The Thalassemia Syndromes. 4.. Aufl. Oxford: Blackwell Scientific Publications; 2001
4 Chui DHK, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood 2003; 101 (3) 791-800
5 Old JM. Screening and genetic diagnosis of haemoglobin disorders. Blood Rev 2003; 17 (1) 43-53
6 Cario H, Kohne E. S1-Leitlinie: Thalassämie. AWMF online 2010; Im Internet: http://www.awmf.org/leitlinien/detail/ll/025-017.html Stand: November 2010
7 Liang ST, Wong VC, So WW et al. Homozygous alpha-thalassaemia: clinical presentation, diagnosis and management. A review of 46 cases. Br J Obstet Gynaecol 1985; 92 (7) 680-684
8 Cavazzana-Calvo M, Payen E, Negre O et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010; 467 (7313) 318-322
9 Piomelli S. The management of patients with Cooleyʼs anemia: transfusions and splenectomy. Semin Hematol 1995; 32 (4) 262-268
10 Cazzola M, Borgna-Pignatti C, Locatelli F et al. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 1997; 37 (2) 135-140
11 Thalassemia International Federation. Guidelines for the clinical management of thalassemia. Nicosia, Cyprus: Team up Creations Ltd.; 2008
12 Cario H, Kohne E, Eber S et al. Beta-Thalassämie. Onkopedia-Leitlinien Hrsg DGHO 2012. Im Internet:. http://www.dgho-onkopediade/de/onkopedia/leitlinien/beta-thalassaemie Stand: Dezember 2012
13 Cario H, Stahnke K, Sander S et al. Epidemiological situation and treatment of patients with thalassemia major in Germany: results of the German multicenter beta-thalassemia study. Ann Hematol 2000; 79 (1) 7-12
14 Taher AT, Musallam KM, Cappellini MD et al. Optimal management of beta thalassaemia intermedia. Br J Haematol 2011; 152 (5) 512-523
15 Taher AT, Musallam KM, Karimi M et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010; 115 (10) 1886-1892
16 Borgna-Pignatti C, Rugolotto S, De Stefano P et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89 (10) 1187-1193
17 Cario H, Grosse R, Janssen G et al. S2-Leitlinie: Diagnostik und Therapie der sekundären Eisenüberladung bei Patienten mit angeborenen Anämien. AWMF online 2010; Im Internet: http://www.awmf.org/leitlinien/detail/ll/025-029.html Stand: April 2010
18 Cario H, Grosse R, Janssen G et al. Guidelines for Diagnostics and Treatment of Secondary Iron Overload in Patients with Congenital Anemia. Klin Padiatr 2010; 222 (6) 399-406
19 Blumberg N, Heal JM, Gettings KF. WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization. Transfusion 2003; 43 (7) 945-952
20 Singer ST, Wu V, Mignacca R et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly asian descent. Blood 2000; 96 (10) 3369-3373
21 Ho HK, Ha SY, Lam CK et al. Alloimmunization in Hong Kong southern Chinese transfusion-dependent thalassemia patients. Blood 2001; 97 (12) 3999-4000
22 Seftel MD, Growe GH, Petraszko T et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103 (1) 333-339
23 Karpinski M, Pochinco D, Dembinski I et al. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 2004; 15 (3) 818-824
24 Schonewille H, Brand A. Alloimmunization to red blood cell antigens after universal leucodepletion. A regional multicentre retrospective study. BrJ Haematol 2005; 129 (1) 151-156
25 van de Watering L, Hermans J, Witvliet M et al. HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: a randomized controlled trial. Transfusion 2003; 43 (6) 765-771
26 Thompson AA, Cunningham MJ, Singer ST et al. Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol 2011; 153 (1) 121-128
27 Saied DA, Kaddah AM, Badr Eldin RM et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent Egyptian thalassemic patients. J Pediatr Hematol Oncol 2011; 33 (6) 409-414
28 Michail-Merianou V, Pamphili-Panousopoulou L, Piperi-Lowes L et al. Alloimmunization to red cell antigens in thalassemia: comparative study of usual versus better-match transfusion programmes. Vox Sang 1987; 52 (1–2) 95-98
29 Spanos T, Karageorga M, Ladis V et al. Red cell alloantibodies in patients with thalassemia. Vox Sang 1990; 58 (1) 50-55
30 Karimi M, Nikrooz P, Kashef S et al. RBC alloimmunization in blood transfusion-dependent beta-thalassemia patients in southern Iran. Int J Lab Hematol 2007; 29 (5) 321-326
31 Pahuja S, Pujani M, Gupta SK et al. Alloimmunization and red cell autoimmunization in multitransfused thalassemics of Indian origin. Hematology 2010; 15 (3) 174-177
32 Ahmed AM, Hasan NS, Ragab SH et al. Red cell alloimmunization and autoantibodies in Egyptian transfusion-dependent thalassaemia patients. Arch Med Sci 2010; 6 (4) 592-598
33 Guirat-Dhouib N, Mezri M, Hmida H et al. High frequency of autoimmunization among transfusion-dependent Tunisian thalassaemia patients. Transfus Apher Sci 2011; 45 (2) 199-202
34 Azarkeivan A, Ansari S, Ahmadi MH et al. Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. Pediatr Hematol Oncol 2011; 28 (6) 479-485
35 Arinsburg SA, Skerrett DL, Kleinert D et al. The significance of a positive DAT in thalassemia patients. Immunohematology 2010; 26 (3) 87-91
36 Noor Haslina MN, Ariffin N, Illuni HI et al. Red cell autoantibodies among thalassaemia patients in Hospital Universiti Sains Malaysia. Singapore Med J 2007; 48 (10) 922-925
37 Ameen R, Al-Shemmari S, Al-Humood S et al. RBC alloimmunization and autoimmunization among transfusion-dependent Arab thalassemia patients. Transfusion 2003; 43 (11) 1604-1610
38 Xu LH, Fang JP, Weng WJ et al. Autoimmune hemolytic anemia in patients with beta-thalassemia major. PediatrHematolOncol 2012; 29 (3) 235-240
39 Ahrens N, Pruss A, Mayer B et al. Association between alloantibody specificity and autoantibodies to red blood cells. Transfusion 2008; 48 (1) 20-24
40 Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86 (6) 480-487
41 Abdu A, Gomez-Marquez J, Aldrich TK. The oxygen affinity of sickle hemoglobin. Respir Physiol Neurobiol 2008; 161 (1) 92-94
42 Ferrone FA. Polymerization and sickle cell disease: a molecular view. Microcirculation 2004; 11 (2) 115-128
43 Olney RS. Preventing morbidity and mortality from sickle cell disease. A public health perspective. Am J Prev Med 1999; 16 (2) 116-121
44 Ballas SK, Dover GJ, Charache S. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol 1989; 32 (2) 104-111
45 Charache S, Terrin ML, Moore RD et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332 (20) 1317-1322
46 Platt OS, Orkin SH, Dover G et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74 (2) 652-656
47 Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol 2012; 159 (4) 394-404
48 Kwiatkowski JL, Cohen AR, Garro J et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. Am J Hematol 2011;
49 Turner JM, Kaplan JB, Cohen HW et al. Exchange versus simple transfusion for acute chest syndrome in sickle cell anemia adults. Transfusion 2009; 49 (5) 863-868
50 Hulbert ML, Scothorn DJ, Panepinto JA et al. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia. J Pediatr 2006; 149 (5) 710-712
51 Mehta SH, Adams RJ. Treatment and prevention of stroke in children with sickle cell disease. Curr Treat Options Neurol 2006; 8 (6) 503-512
52 Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005; 353 (26) 2769-2778
53 Adams RJ, McKie VC, Hsu L et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339 (1) 5-11
54 Pegelow CH, Adams RJ, McKie V et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995; 126 (6) 896-899
55 Smith-Whitley K, Thompson AA. Indications and complications of transfusions in sickle cell disease. Pediatr Blood Cancer 2012; 59 (2) 358-364
56 Aygun B, Wruck LM, Schultz WH et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. Am J Hematol 2012; 87 (4) 428-430
57 Ware RE, Schultz WH, Yovetich N et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediat Blood Cancer 2011; 57 (6) 1011-1017
58 Casella JF, King AA, Barton B et al. Design of the silent cerebral infarct transfusion (SIT) trial. Pediatr Hematol Oncol 2010; 27 (2) 69-89
59 Koshy M, Burd L, Wallace D et al. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med 1988; 319 (22) 1447-1452
60 Miller ST, Wright E, Abboud M et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001; 139 (6) 785-789
61 Lottenberg R, Hassell KL. An evidence-based approach to the treatment of adults with sickle cell disease. Hematology Am Soc Hematol Educ Program 2005; 58-65
62 Miller ST. How I treat acute chest syndrome in children with sickle cell disease. Blood 2011; 117 (20) 5297-5305
63 Quirolo K. How do I transfuse patients with sickle cell disease?. Transfusion 2010; 50 (9) 1881-1886
64 Vichinsky EP, Haberkern CM, Neumayr L et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 1995; 333 (4) 206-213
65 Wahl S, Quirolo KC. Current issues in blood transfusion for sickle cell disease. Curr Opinion Pediatr 2009; 21 (1) 15-21
66 Ness PM. To match or not to match: the question for chronically transfused patients with sickle cell anemia. Transfusion 1994; 34 (7) 558-560
67 Vichinsky EP, Earles A, Johnson RA et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322 (23) 1617-1621
68 Aygun B, Padmanabhan S, Paley C et al. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002; 42 (1) 37-43
69 Olujohungbe A, Hambleton I, Stephens L et al. Red cell antibodies in patients with homozygous sickle cell disease: a comparison of patients in Jamaica and the United Kingdom. Br J Haematol 2001; 113 (3) 661-665
70 Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012; 120 (3) 528-537
71 Reid ME, Lomas-Francis C. The Blood Group Antigen FactsBook. 2nd. ed. Waltham, MA: Elsevier Academic Press; 2004
72 Natukunda B, Schonewille H, Ndugwa C et al. Red blood cell alloimmunization in sickle cell disease patients in Uganda. Transfusion 2010; 50 (1) 20-25
73 Castellino SM, Combs MR, Zimmerman SA et al. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. Br J Haematol 1999; 104 (1) 189-194
74 Gibson BE, Todd A, Roberts I et al. Transfusion guidelines for neonates and older children. Br J Haematol 2004; 124 (4) 433-453
75 Josephson CD, Su LL, Hillyer KL et al. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfus Med Rev 2007; 21 (2) 118-133
76 Vichinsky EP, Luban NL, Wright E et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41 (9) 1086-1092
77 Castro O, Sandler SG, Houston-Yu P et al. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 2002; 42 (6) 684-690
78 Lasalle-Williams M, Nuss R, Le T et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 2011; 51 (8) 1732-1739
79 Tahhan HR, Holbrook CT, Braddy LR et al. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion 1994; 34 (7) 562-569